Autologous peripheral blood progenitor cell transplantation in patients with high-risk myelodysplastic syndromes

Pathol Biol (Paris). 1997 Oct;45(8):651-5.

Abstract

Most patients with myelodysplastic syndromes (MDSs) who achieve a complete remission under aggressive chemotherapy develop a recurrence within 18 to 24 months. Autologous stem cell transplantation has therefore been suggested as a potential means of increasing treatment efficacy. As compared with bone marrow stem cell autografts, peripheral stem cell autografts have a higher harvesting yield and a shorter duration of aplasia after reinjection. Also, the results reported herein suggest that polyclonal stem cells harvested after chemotherapy-induced aplasia and growth factor therapy are capable of ensuring normal hematopoiesis and may provide prolonged remissions in some patients.

MeSH terms

  • Adult
  • Drug Therapy, Combination
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / therapy*
  • Remission Induction / methods
  • Risk Factors